Thanks so much @MarkTysonMD & @JoshMeeks !! Very appreciative of both of your support and help with the GAIN trial A032303 @ALLIANCE_org @SWOG @eaonc @NRGonc @theNCI

Presented at #ASCO26: In high-risk localized prostate cancer, ADT plus apalutamide led to a pathological complete response or minimal residual disease and 5-year metastasis-free survival in a greater percentage of patients than ADT plus placebo. Full phase 3 PROTEUS trial results: nej.md/3RuNe00 Editorial: A Watershed Moment in the Perioperative Treatment of Prostate Cancer nej.md/4dLeiiW @ASCO

We ran a mock ODAC for sasanlimab and durvalumab in high risk NMIBC. Results showed one of the agents received more support than the other. This felt surprising and is timely in vote of the recent FDA decisions. #ASCO26 👉 open.spotify.com/episode/2jM…

#FDA approves a treatment for high-risk non-muscle invasive bladder cancer. fda.gov/drugs/resources-info…

GI-Coffee study. Coffee vs alvimopan for MIBC after cystectomy for bowel recovery. Great study. Worry about contamination of baseline coffee use across both arms.

Please open and enroll to GAIN. @eugene_pietzak gem-bcg. Bcg exposed. Great trial. We have open and enrolling @NM_Urology

MR3🌑 ErdaiDRS. BCG unresponsive. (It’s like SR5-> FGFR3)

MR2🌑 FGFR3 agnostic. Ablative (noTURBT) for IR. results coming.

TIP#5 Tyra-300 IR NMIBC. oral FGFR3

TIP#3 Enlighted Ph3. VTP for UTUC. very reasonable response for LG UTUC

TIP#2. So excited for ARCIS. @SWOG. First RCT of BCG unresponsive NMIBC. CRETO-gem vs gem-doce. @MarkTysonMD @cgoncology

TIP#1 Bel-sar. Novel neoajuvant injection mechanism. #AUA2026

Come join us for a deep dive into Clinical Trials in Progress - Hall B, The Square, Learning Lab ... at 9 am ET TODAY #AUA26

The FDA approves the signatera ctDNA assay for muscle invasive bladder cancer patients post surgery. This is based on the results of Imvigor011 study (atezo vs placebo in ctDNA positives, surveillance for the ctDNA negatives). It opens a new chapter for personalised therapy in urothelial cancer. Focusing on early treatment for those patients that need it and sparing those at lower risk potentially harmful treatment makes sense. ‘It is the first companion diagnostic approval in the field of blood-based MRD.’ natera.com/company/news/sign…

Very reasonable responses - Legend on its way

Congratulations to the newly awarded 2026 National Residency Abstract Olympics winners! 🏆 @CleClinicUro @NM_Urology @WCMUrology #AUA26

Small numbers but improved cystectomy free survival and lower rates in bcg durva arms of Potomac. Seems less bcg unresponsive. This may be the piece that matters #bladdercancer. #AUA26

Perioperative durvalumab (12 months) with neoadjuvant EV (3 cycles) shows ‘statistically significant and clinically meaningful’ improved EFS and OS vs cystectomy alone in MIBC (like KN905 (EVP cs cystectomy)). The shorter period of EV is the major difference in trial designs. Details of efficacy and toxicity will be important. The 3rd arm, where tremelimumab was added as a triplet, did not hit OS at this stage. astrazeneca.com/media-centre… @OncoAlert

Wow